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I20 in adenocarcinoma without smoking (39.2±35.1%. n=6) was higher 
than that of adenocarcinoma with smoking (2.2±5.0%, n=10, p=0.001), 
and that of non-adenocarcinoma (16.9±23.6%, n=6, p=0.09). Gene 
mutation analysis was performed in 2 of 3 adenocarcinomas without 
smoking, which showed high I20 values (76.3%, 72.1%, and 63.0%). 
Gene mutation in EGFR was observed in these specimens. Cut-off 
inhibition rate of 50% appears to be suitable for the concentration of 20 
μg/ml.
Conclusion: HDRA appears to be applicable to evaluate the sensitiv-
ity for geﬁtinib in non-small cell lung cancer. It will provide more 
convenient method to predict the response for EGFR-TKIs in the 
patients with non-small cell lung cancer, whose fresh tumor specimens 
are available.
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Background: Clinical experience with geﬁtinib has suggested that 
there are subgroups of patients with non-small-cell lung cancer 
(NSCLC) that demonstrate dramatic responses to this agent. Correla-
tion between geﬁtinib sensitivity and adverse events in NSCLC re-
mains controversial. Rash, the most commonly reported adverse effect 
of anti-EGFR therapy, has been examined as a potential marker of re-
sponse and survival. Several trials evaluating anti-EGFR therapies have 
reported a positive correlation between rash and response and even rash 
and survival. In this retrospective analysis of NSCLC patients treated 
with geﬁtinib we have assessed adverse events and their relationship to 
treatment outcome.
Methods: 690 NSCLC patients were enrolled since January 2002 
till September 2005 for the treatment with geﬁtinib under the EAP 
program in the Czech Republic. Correlations among clinicopathologi-
cal characteristics, geﬁtinib sensitivity, and time to progression (TTP), 
survival and adverse events were studied. 
Results: 46% of patients had no adverse event. Skin rash was the most 
frequent adverse event (42% any grade, G3-4: 5%), diarrhea occurred 
in 18% (G3-4: 2%), nausea and vomiting in 15% (G3-4: 2%) and liver 
toxicity in 6% (G3: 0.1%). Interstitial lung disease was not observed, 
pulmonary adverse events were pneumonia and bronchitis in 1.5% of 
patients. 27% of patients had 2 and more adverse events. Treatment 
was preliminary terminated due to toxicity in 10%. Skin rash was more 
frequent in men (44%) then in women (35%), p = 0.055, other toxicity 
in subgroups according to gender, stages, histopathology and pretreat-
ment did not differ signiﬁcantly. The patients with rash or diarrhea had 
longer time to progression (median 5.2 versus 2.7 months, p = 0.001) 
and survival (median 10.3 versus 5.0 months, p = 0.001) as the patients 
without toxicity. Rash was signiﬁcantly correlated with longer survival 
and TTP in all subgroups according to gender and histopathology. 
Response rate and clinical beneﬁt did not differ in subgroups according 
to toxicity.
Conclusions: In this group of 690 geﬁtinib treated NSCLC the ex-
pected frequency and spectrum of adverse events were observed. Most 
frequent toxicity was skin rash and diarrhea. Toxicity grade 3 and 4 did 
not exceed 5%. Patients with adverse events, particularly with the rash, 
had longer survival and time to progression.
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Background: Geﬁtinib, a selective inhibitor of epidermal growth factor 
receptor (EGFR) tyrosine kinase, has been approved effective in local 
advanced or metastatic non-small cell lung cancer (NSCLC) previously 
treated with chemotherapy in Asian patients. Asian ethnicity, gender, 
smoking history, adenocarcinoma histology were considered associate 
with geﬁtinib response and survival. However, these predictive factors 
of geﬁtinib efﬁcacy (response or stabilization) and survival are still 
unclear in Asian population. 
Methods: Tumor response, survival and the clinicopathologic factors 
of 256 NSCLC patients treated between Sep.2002 and Mar. 2005 were 
collected retrospectively from the expanded access program (EAP) and 
multicenter registration trial of geﬁtinib in China. Pearson Chi-square 
test and Logistic regression test were performed respectively as uni-
variate and multivariate analyses of geﬁtinib response. Overall surviv-
als between groups with different predictive factors were compared by 
log-rank tests. Multivariate analysis was performed to identify factors 
that independently predict for survival. 
Results: A total of 256 patients were included in this analysis. Objec-
tive response rate was 24.6% (95% conﬁdence interval [CI]: 19.3%-
29.9%) and disease control rate was 54.7% (95%CI: 48.6%-60.8%). 
Objective response rate was statistically signiﬁcant higher in patients 
with younger age(≤65 years), smoking history, adenocarcinoma and 
longer interval from diagnosis to geﬁtinib treatment (≥6 months) in 
univariate analysis (p<0.05), but only younger patients(≤65 years) had 
statistically signiﬁcant higher response rate in multivariate analysis 
(p<0.05). Disease control rate was statistically signiﬁcant higher in 
adenocarcinoma and patients with controlled disease (CR+PR+SD) 
to most recent chemotherapy in multivariate analysis (p<0.05). The 
median follow-up duration was 13.1 months (range, 0.5-38.8). The me-
dian survival was 12.9 months (95% CI: 9.9-15.9) and 1-year survival 
was 51.8%. Signiﬁcant independent predictive factors associated with 
longer survival in multivariate analysis were good performance status 
(score 0-1) and controlled disease (CR+PR+SD) to geﬁtinib (p<0.05). 
Conclusions: Geﬁtinib is effective in local advanced or metastatic 
NSCLC patients in China. In Chinese NSCLC population, younger age 
(≤65 years), adenocarcinoma and controlled disease (CR+PR+SD) to 
most recent chemotherapy were predictive factors in multivariate anal-
ysis for geﬁtinib efﬁcacy (response or stabilization); good performance 
status (score 0-1) and controlled disease (CR+PR+SD) to geﬁtinib were 
independent prognostic factors for survival. 
